Hutchmed's (HKG:0013) ORPATHYS will continue to be included in the updated National Reimbursement Drug List effective Jan. 1, 2025, on the same terms, a Thursday bourse filing said.
ORPATHYS is used for the treatment of certain patients with non-small cell lung cancer with MET exon 14 skipping alterations.
ORPATHYS was first included in the list on March 1, 2023.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。